Dr. Julie Hambleton is a senior biotechnology executive with over 20 years of experience in clinical drug development. In addition to SpringWorks, Julie also serves as a member of the Board of Directors for IGM Biosciences and Arch Oncology. She served as interim President and Chief Executive Officer of Arch Oncology until 2021, and prior to that, Julie served as Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences until her retirement in 2020. Before IDEAYA, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Earlier, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics. Julie began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin®. Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, an M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.